CASE STUDY | PAYER COMMUNICATIONS
When CNS Access Required More Than Value, We Reframed the Pathway.
THE CHALLENGE
Communicating Value Early in a Complex CNS Access Environment
The introduction of CMS Coverage with Evidence Development, layered onto an accelerated approval pathway based on Phase 2 biomarker data, fundamentally expanded the scope of pre- and peri-launch stakeholder engagement.
While early payer communication is standard, stakeholders needed to engage beyond value exchange to align on evidence-generation requirements and establish new care pathways and operational infrastructure, spanning infusion capacity, site-of-care coordination, biomarker-confirmed diagnosis, genetic testing, and ongoing safety monitoring.
THE BREAKTHROUGH
Reframing Payer Engagement from Value Communication to End-to-End Care Pathway Education
Rather than relying on a traditional value narrative alone, BGBx recognized that decision-makers needed a clear understanding of how a novel neurology therapy would be implemented in practice, clinically, operationally, and economically.
Using our 3D Science approach, integrating clinical science, data science, and behavioral science, we developed and validated a payer value proposition structured around the full patient journey.
The resulting materials enabled field medical, HEOR, and account teams to communicate consistently with payers on:
- Patient identification requirements, including diagnostic and biomarker confirmation
- Treatment administration logistics, including site-of-care and delivery considerations
- Safety monitoring protocols requiring ongoing imaging or follow-up
- The downstream economic impact of disease progression and early intervention
By shifting the focus from isolated value messages to a comprehensive view of the treatment pathway, this approach equipped payers to evaluate the full set of requirements needed to support access and implementation.
THE RESULTS
Early and Repeated Value Communication Strengthened CNS Access Readiness
Our approach empowered decision-makers to engage with the value story over time. At launch, many had already evaluated the therapy and updated pathways and formularies, supporting a more prepared and informed access environment.
Accelerated
Timeline
Value communication delivered early
Pre-Approval
Engagement
PIE and value presentations
Sustained
Exposure
Value story repeated as data evolved
Our Perspectives on Advertising
2026 Oncology Market Access Trends
Implications of the IRA’s Maximum Fair Price (MFP) Negotiations
340B Drug Discount Program
Let’s Plan Your Next CNS Breakthrough
At BGBx, we deliver breakthrough commercial solutions by aligning clinical, economic, and access value, ensuring your value story is understood, trusted, and actionable across stakeholders.
